Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxcarbazepine: clinical development program

S Schwabe1

  • 1Pharmaceutical Division, Ciba-Geigy Ltd., Basel, Switzerland.

Epilepsia
|January 1, 1994
PubMed
Summary

Oxcarbazepine (OCBZ) offers comparable efficacy to carbamazepine (CBZ) with fewer side effects and drug interactions. Its favorable metabolic profile allows for higher dosages and simplified administration, making it a viable alternative for many epilepsy patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histo-morphological effects on equine synovium after arthroscopic synovectomy using two different motorized synovial resectors and two different intensities.

Journal of equine veterinary science·2023
Same author

Inpatient monotherapy studies in epilepsy: pro.

Epilepsy & behavior : E&B·2003
Same author

Monotherapy comparative trials: placebos and suboptimal comparators.

Epilepsy research·2001
Same author

The Neurotoxicity Scale: the validity of a patient-based scale, assessing neurotoxicity.

Epilepsy research·1995
Same author

Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review.

Epilepsia·1994
Same author

Clinical development outlook of oxcarbazepine.

Epilepsia·1994

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Neurology

Background:

  • Oxcarbazepine (OCBZ) is an antiepileptic drug related to carbamazepine (CBZ).
  • Further clinical data is required for broader international registration of OCBZ.
  • OCBZ exhibits a distinct metabolic profile compared to CBZ, with minimal hepatic enzyme induction.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Oxcarbazepine (OCBZ).
  • To compare OCBZ with carbamazepine (CBZ) regarding side effects and drug interactions.
  • To assess the pharmacokinetic properties and dosing recommendations for OCBZ.

Main Methods:

  • Clinical studies were conducted to gather data on OCBZ.
  • Comparative analysis of efficacy and side effect profiles between OCBZ and CBZ.
  • Pharmacokinetic assessments including half-life and drug interactions were performed.

Main Results:

  • OCBZ demonstrates comparable efficacy to CBZ but with significantly fewer limiting side effects.
  • OCBZ exhibits markedly fewer interactions with concomitant medications due to low protein binding and minimal hepatic enzyme induction.
  • Dosage adjustments for OCBZ are generally not required in renal impairment unless creatinine clearance is below 30 ml/min.

Conclusions:

  • Oxcarbazepine (OCBZ) presents a favorable alternative to carbamazepine (CBZ) due to improved tolerability and a reduced potential for drug interactions.
  • The pharmacokinetic profile of OCBZ supports twice-daily administration.
  • Further studies are planned to investigate OCBZ's effects on hepatic enzymes at higher doses and on sex hormones, as well as its use in specific populations.

Related Experiment Videos